Argenx
ARGX
#542
Rank
NZ$67.18 B
Marketcap
$1,124
Share price
0.33%
Change (1 day)
86.63%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

P/E ratio for Argenx (ARGX)

P/E ratio as of December 2024 (TTM): -152

According to Argenx 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -151.933. At the end of 2022 the company had a P/E ratio of -28.9.

P/E ratio history for Argenx from 2017 to 2021

PE ratio at the end of each year

Year P/E ratio Change
2022-28.9

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.